Inventor · name-matched record
SCHLEGEL MARK K
6 granted patents·2 pending applications·0 citations·filing 2020–2025
65Inventor score
Files withALNYLAM PHARMACEUTICALS INC8
This identity is grouped by exact name match (no disambiguated inventor record was available for these filings) — it may combine same-named inventors.
Top patents by PatentIndex Score
8 records- 0186US12584130B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Mar 24, 2026·0 cites·36 claims
- 0277US2026028631A1KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 0375US2026049312A1Complement component c3 irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 0466US12545914B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Feb 10, 2026·0 cites·84 claims
- 0565US12553053B2Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Feb 17, 2026·0 cites·23 claims
- 0665US12522822B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 13, 2026·0 cites·25 claims
- 0763US12516322B2Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Jan 6, 2026·0 cites·29 claims
- 0855US12565653B2ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Mar 3, 2026·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when SCHLEGEL MARK K files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: exact name match across USPTO filings. How scoring works →